10 Lymphoma Clinical Trials in Dallas, TX (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Lymphoma Studies in Dallas

NCT07439653Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL...

Dallas, TXPHASE1155 participantsTORL Biotherapeutics, LLC

View Study Details

NCT06116110Recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1....

Dallas, TX150 participantsMiltenyi Biomedicine GmbH

View Study Details

NCT04329728Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) ...

Dallas, TXPHASE1144 participantsAVM Biotechnology Inc

View Study Details

NCT03666000Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T,...

Dallas, TXPHASE1135 participantsImugene Limited

View Study Details

NCT05685173Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-...

Dallas, TXPHASE1107 participantsRegeneron Pharmaceuticals

View Study Details

NCT04502394Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia...

Dallas, TXPHASE184 participantsKartos Therapeutics, Inc.

View Study Details

NCT06357754Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified ...

Dallas, TX50 participantsBristol-Myers Squibb

View Study Details

NCT05852717Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Da...

Dallas, TXPHASE235 participantsDipenkumar Modi

View Study Details

NCT06768905Recruiting

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with R...

Dallas, TXPHASE130 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06343311Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in ad...

Dallas, TXPHASE127 participantsEstrella Biopharma, Inc.

View Study Details

About Lymphoma Clinical Trials in Dallas

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 10 lymphoma clinical trials recruiting participants in Dallas, TX. These studies are seeking a combined 917 participants. Research is being sponsored by TORL Biotherapeutics, LLC, Miltenyi Biomedicine GmbH, AVM Biotechnology Inc and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Dallas — FAQ

Are there lymphoma clinical trials in Dallas?

Yes, there are 10 lymphoma clinical trials currently recruiting in Dallas, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 10 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated October 21, 2026 from ClinicalTrials.gov